Type 2 diabetes and vascular disease
====================================

Vascular complications represent the leading cause of mortality and morbidity in patients with diabetes ([@b52]). Approximately 65% of deaths among patients with diabetes are due to cardiovascular and cerebrovascular diseases, including myocardial ischemia and stroke ([@b33]; [@b44]; [@b28]). Adverse outcomes are also associated with microvascular diseases such as nephropathy, neuropathy, and retinopathy, which contribute significantly to the development of end-stage renal disease, foot ulcers, and blindness ([@b44]; [@b65]). Type 2 diabetes is the clinical manifestation of long-term metabolic abnormalities involving multiple organs and hormonal pathways that impair the body\'s ability to maintain glucose homeostasis ([@b3]). Pancreatic beta-cell dysfunction and insulin resistance are widely recognized as the cardinal defects that lead to chronic hyperglycemia, which is a major contributor of diabetic vascular complications. At the cellular level, elevated glucose concentrations cause increased production of reactive oxidant species (ROS) that ultimately contribute to the deterioration of vascular health through multiple pathways ([@b10]). Effects of hyperglycemia-induced damage include endothelial dysfunction, inflammation, and the promotion of atherogenic conditions ([@b15]; [@b1]).

In parallel with impaired glucose homeostasis, patients with type 2 diabetes often have an associated constellation of cardiovascular disease (CVD) risk factors including hypertension, abdominal obesity, atherogenic dyslipidemia (characterized by hypertriglyceridemia and low levels of high-density lipoprotein cholesterol \[HDL-C\]), chronic inflammation, and alterations in thrombolytic parameters ([@b39]; [@b64]; [@b6]; [@b28]). It is not surprising that type 2 diabetes has been implicated as a coronary heart disease (CHD) "risk equivalent", carrying an absolute risk for coronary heart events similar to that for nondiabetic individuals with established CHD ([@b53]).

Obesity is strongly associated with type 2 diabetes and is present in approximately 80%--95% of type 2 diabetes cases ([@b4]). Obesity also exacerbates the metabolic abnormalities of type 2 diabetes, particularly hyperglycemia, hyperlipidemia, and hypertension ([@b39]; [@b48]). Additionally, the risk of developing type 2 diabetes increases exponentially in relation to body mass index (BMI) ([@b50]). This is particularly evident in children and adolescents, in whom obesity is on the rise and the incidence of type 2 diabetes is nearing that of type 1 ([@b40]). Management of weight gain in patients with type 2 diabetes, particularly in those already overweight, is important to improving glycemic control and reducing CV risk ([@b2]).

Results from the United Kingdom Prospective Diabetes Study (UKPDS) of intensively treated patients with type 2 diabetes demonstrated the beneficial impact of glycemic control for reducing microvascular complications, and implicated a role for hyperglycemia in macrovascular disease ([@b70]). Notably, these data indicated that any improvement in glycemic control has a beneficial impact in reducing diabetes-related complications ([@b66]). Near-normalization of glycemia is possible with current diabetes therapies; however, patients continue to experience excessive diurnal glucose fluctuations ([@b51]; [@b35]). In addition, a majority of therapies are typically accompanied by undesired weight gain and an increased risk of hypoglycemia, particularly when treatment includes insulin and several oral antihyperglycemic agents ([@b22]; [@b63]). Therefore, pharmacological agents that provide glycemic control with a reduced risk of severe hypoglycemia and reductions in body weight would present a distinct treatment option compared with currently available therapies for patients with type 2 diabetes.

Exenatide, an incretin mimetic
==============================

Glucagon-like peptide-1 (GLP-1) is an insulinotropic gut hormone, or incretin, that is partly responsible for the more robust insulin secretory response elicited by enteral glucose administration compared with that measured after isoglycemic intravenous glucose infusion ([@b61]; [@b18]; [@b47]). Partly due to reduced postprandial secretion of GLP-1, patients with type 2 diabetes exhibit an impaired incretin response compared with individuals with normal glucose tolerance ([@b54]; [@b68]). Exogenous administration of GLP-1 has been shown to elicit glucoregulatory effects in patients with type 2 diabetes ([@b55]; [@b74]). More recently, preclinical and clinical studies have shown that GLP-1 also has salutary cardiovascular effects ([@b58]; [@b9]). In particular, clinical studies have demonstrated that GLP-1 ameliorates endothelial dysfunction in patients with type 2 diabetes with established CHD, and can improve left ventricular heart function in patients with acute myocardial infarction ([@b57]; [@b58]). Despite these features, the therapeutic potential of GLP-1 is limited due to its rapid degradation by the ubiquitous enzyme, dipeptidyl peptidase-IV (DPP-IV) ([@b55]; [@b19]; [@b74]). The circulating half-life of GLP-1 is approximately 1--2 minutes, which precludes the maintenance of therapeutic levels by subcutaneous dosing ([@b25]). Several approaches have been undertaken to develop agents that replicate or replace the actions of GLP-1, which are in various stages of clinical development ([@b36]; [@b20]). The first of these GLP-1-like molecules to receive regulatory approval for the treatment of type 2 diabetes is the incretin mimetic, exenatide.

Exenatide (exendin-4) is a 39 amino acid peptide originally isolated from the salivary secretions of the lizard *Heloderma suspectum* (Gila monster) that is approved in the US as an adjunctive therapy to metformin and/or sulfonyureas in patients with type 2 diabetes ([@b27]; [@b56]; BYETTA® prescribing information \[PI\], Amylin Pharmaceuticals Inc, San Diego, CA, USA). Exenatide shares 53% amino acid sequence identity with human GLP-1 and has been shown in vitro to mediate its insulinotropic effects through binding to the GLP-1 receptor on pancreatic beta cells ([@b27]; [@b31]).

Exenatide exhibits a higher potency (ED~50~ \[effective dose 50\]; acute dose-response in animal models) and longer duration of action relative to GLP-1 largely due to its pharmacokinetic profile ([@b73]; [@b46]). Exenatide lacks a penultimate alanine that directs DPP-IV cleavage, rendering it more proteolytically stable than GLP-1 ([@b67]). Also, significant differences in clearance rates between GLP-1 and exenatide have been reported, with the plasma clearance of exenatide approximately 10% that of GLP-1 ([@b60]). The circulating half-life of exenatide is 2.4 hours and its effects are detectable for approximately 6--8 hours postadministration ([@b30]; [@b46]; BYETTA PI).

The glucoregulatory effects of exenatide are achieved through a range of actions similar to native GLP-1, including the enhancement of glucose-dependent insulin secretion; suppression of inappropriately elevated postprandial glucagon secretion; slowing of gastric emptying; and reduction in food intake ([Table 1](#tbl1){ref-type="table"}) (reviewed in [@b56]). In addition, exenatide restores insulin responses and secretory patterns typically deficient and abnormal in patients with type 2 diabetes ([@b29]). These mechanisms work in concert to reduce fasting and postprandial glucose concentrations by modulation of both glucose appearance (slowing of gastric emptying, suppression of glucagon secretion, reduction of food intake) and glucose disposal (enhancement of insulin secretion) in the circulation.

###### 

Primary glucoregulatory actions of exenatide

  ------------------------------------------------
  • enhances glucose-dependent insulin secretion
  • restores 1st phase insulin secretion
  • slows gastric emptying
  • suppresses inappropriate glucagon secretion
  • reduces food intake
  ------------------------------------------------

Clinical studies with exenatide
===============================

Glycemic effects
----------------

Prospective epidemiological studies have demonstrated the relationship between the incidence of microvascular and macrovascular disease and hyperglycemia ([@b17]; [@b66]). Increased risk of vascular disease is continuous and incrementally graded across fasting plasma glucose (FPG) concentrations, plasma glucose concentrations after an oral glucose challenge, and average levels of glycemia (HbA~1c~) ([@b66]). In the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk), levels of HbA~1c~ were found to be continuously related to the increased risk of all-cause mortality, CVD, and ischemic disease, with a 1% increase in HbA~1c~ associated with a 28% increase in the risk of death ([@b43]). Increasing evidence has emphasized the role of postchallenge hyperglycemia measured either 1--2 hours after a glucose load as a direct and independent risk factor for CVD beyond the risk associated with FPG alone ([@b8], [@b16]; [@b37]). In particular, the DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) and Framingham Offspring Study designated postchallenge hyperglycemia as an independent risk factor for CVD ([@b21]; [@b49]). Moreover, the prognostic significance of postchallenge hyperglycemia is further supported by studies indicating that impaired glucose tolerance (IGT), rather than impaired fasting glucose (IFG), is a critical determinant of fatal CVD ([@b5]; [@b69]; [@b13]).

Numerous studies have established the effective glucoregulatory actions of exenatide as evidenced by reductions in FPG concentrations, postprandial plasma glucose (PPG) concentrations, and HbA~1c~ ([@b30]; [@b45]; [@b11]; [@b23]; [@b41]; [@b62]). The antihyperglycemic effects of exenatide are mediated by the key actions of enhancement of glucose-dependent insulin secretion, suppression of inappropriate glucagon secretion, and slowing of gastric emptying.

Acute glucoregulatory effects of exenatide were exemplified in a 28-day study in patients with type 2 diabetes treated with diet, sulfonylureas, and/or metformin. Compared with placebo, exenatide-treated patients showed significant mean reductions from baseline in HbA~1c~ of approximately 0.9% ([@b30]). Reductions in HbA~1c~ were observable after 1 month of exenatide treatment, a notable response given that HbA~1c~ reflects sustained glycemic changes over the preceding 3 months. Exenatide treatment also resulted in marked reductions in postprandial glycemia ([@b30]). Glucose profiles during ingestion of a mixed meal showed significant postprandial glucose-lowering effects that were observable from the first day of exenatide treatment compared with placebo, and were sustained to day 28 ([@b30]). Since postprandial hyperglycemia may be a stronger predictor of vascular disease than elevated FPG concentrations in patients with diabetes ([@b16]; [@b37]), pharmacological control of meal-time glucose concentrations with exenatide has the potential to reduce the incidence of long-term complications in patients with type 2 diabetes. Additional effects reported for exenatide include reductions in the magnitude of diurnal glucose excursions ([@b34]) and reductions in postprandial triglyceride concentrations ([@b45]).

Worsening beta-cell function is thought to be responsible for the progressive deterioration in glycemic control that occurs almost universally over time in patients with type 2 diabetes ([@b38]). Therefore, pharmacological agents that have the potential to reduce demand on residual beta-cell function and improve beta-cell responsiveness may positively impact long-term patient outcomes related to disease progression and development of vascular complications. One of the principal actions of exenatide is the enhancement of insulin secretion from beta cells ([@b26]). Of clinical significance is that the insulinotropic effects of exenatide are glucose-dependent ([@b24]). In an acute study, patients receiving varying doses of exenatide following an overnight fast showed dose-dependent reductions in plasma glucose concentrations during a subsequent 8-hour period while the prevailing glucose concentration was elevated ([@b45]). As euglycemia was restored, basal insulinemia was re-established ([@b45]). Thus, physiological glucose-sensing mechanisms assure that insulin secretion is coupled to glycemia, resulting in a reduced risk of hypoglycemia. This action of exenatide is in contrast to insulin secretagogues such as sulfonylureas, which increase insulin secretion regardless of glucose concentrations.

Early beta-cell dysfunction is manifested as a loss of the first phase insulin secretion, a rapid burst of insulin in response to an intravenous glucose bolus that is characteristically absent in patients with IGT and type 2 diabetes ([@b14]). In a study comparing patients with type 2 diabetes with healthy individuals, both first-phase insulin secretion and second-phase insulin secretion were significantly increased in patients with type 2 diabetes treated with intravenous exenatide compared with saline ([@b29]). Further, exenatide restored insulin secretory patterns, typically lacking in patients with type 2 diabetes, to those observed in healthy subjects ([@b29]). Additional results from surrogate assays of beta-cell function, such as the proinsulin to insulin ratio, suggested improved beta-cell secretory function with exenatide compared with placebo, providing further evidence of exenatide-mediated improvements in beta-cell health ([@b30]; [@b11]; [@b23]).

The safety and efficacy of exenatide were demonstrated in 3, 30-week clinical trials in approximately 1400 patients with type 2 diabetes unable to achieve glycemic control with metformin, a sulfonylurea, or both ([@b11]; [@b23]; [@b41]). All three studies reported that 30 weeks of exenatide treatment, administered subcutaneously at 5 μg or 10 μg twice daily, resulted in significant reductions in HbA~1c~, FPG concentrations and postprandial plasma glucose concentrations compared with placebo ([@b11]; [@b23]; [@b41]). Mean reductions from baseline in HbA~1c~ ranged from −0.9 to −0.8% in the 10 μg exenatide groups compared with mean increases of +0.1 to +0.2% in the placebo groups ([Figure 1](#fig1){ref-type="fig"}). Consistent with these results, a cohort of 393 patients completing 82 weeks of exenatide treatment in open-label extensions of the placebo-controlled trials showed sustained reductions in HbA~1c~ of approximately −1.1%, demonstrating the durability of the exenatide treatment response ([@b7]).

![Results from pivotal studies with exenatide. Mean ± SE changes from baseline in glycemia and body weight in patients with type 2 diabetes treated with exenatide or placebo for 30 weeks on a background of metformin, sulfonylureas or a combination of metformin and sulfonylureas.](vhrm0201-069-f1){#fig1}

In a phase 3, noninferiority study, exenatide was directly compared with basal insulin (insulin glargine) in patients with type 2 diabetes inadequately controlled with metformin or sulfonylureas ([@b34]). Results from the 26-week, open-label study showed that exenatide achieved similar reductions in HbA~1c~ to insulin glargine (exenatide: −1.0%, glargine: −1.1%). Comparison of self-monitored blood glucose profiles in treated patients showed improvements in postprandial glucose control and in 24-hour glucose profiles with exenatide, whereas glargine mainly lowered FPG concentrations, but did not alter the magnitude of postprandial glucose excursions throughout the day ([@b34]). Results from this comparator study indicate that exenatide may have a role as an appropriate alternative to basal insulin in patients with type 2 diabetes failing to achieve treatment targets on combination oral medications.

Weight effects
--------------

Excess weight causes deleterious effects on glucose metabolism due predominantly to insulin resistance and elevated levels of free fatty acids. Numerous studies have demonstrated that even modest weight loss (5% to 10%) markedly improves glycemic control in patients with type 2 diabetes and reduces the severity of vascular risk factors and comorbidities ([@b32]; [@b72]; [@b71]). It is well recognized that the cornerstone of managing diabetes is diet and exercise modification to achieve significant and sustained weight loss. Managing body weight gain becomes increasingly challenging given that intensive glucose control with most therapies may be accompanied by substantial weight gain ([@b63]).

Studies with exenatide demonstrate that improvements in glycemic control in patients with type 2 diabetes are accompanied by significant reductions in body weight ([@b11]; [@b23]; [@b41]). In the placebo-controlled, 30-week trials, mean reductions from baseline in body weight were observed, ranging from −2.8 kg to −1.6 kg in the 10 μg dosing group after 30 weeks of exenatide treatment, compared with +0.9 kg to +0.3 kg in the placebo group ([Figure 1](#fig1){ref-type="fig"}) ([@b11]; [@b23]; [@b41]). Positive effects of exenatide on body weight were further evident when treatment effects were directly compared with those with insulin glargine in the 26-week noninferiority study. Similar reductions in HbA~1c~ of approximately −1% were demonstrated with each treatment, however, exenatide treatment resulted in a mean reduction of −2.3 kg in body weight, whereas glargine treatment resulted in a mean increase of +1.8 kg in body weight ([@b34]).

An interim assessment of ongoing, open-label extensions of the 30-week, placebo-controlled trials, a subgroup of patients completing 82 weeks of exenatide treatment (n = 265) showed sustained mean reductions in HbA~1c~ of −1.2% and progressive reductions of body weight of −4.6 kg ([Figure 2](#fig2){ref-type="fig"}) ([@b41]). It is notable that this body weight loss was observed without any protocol specified diet and exercise advice, and with a concurrent HbA~1c~ reduction of approximately 1%. The impact of reductions in HbA~1c~ and body weight over 82 weeks was further evaluated using several risk markers of CVD ([Table 2](#tbl2){ref-type="table"}). Significant improvements from baseline to Week 82 in circulating concentrations of triglycerides, HDL-C, and diastolic blood pressure were observed ([Table 2](#tbl2){ref-type="table"}) ([@b41]). Additional analyses explored parameters by quartiles wherein the cohort was subdivided into 4 equal-sized groups based on their absolute change in weight. Findings from this analysis showed that the quartile with the greatest reduction in weight showed the greatest improvements in cardiovascular risk factors ([@b41]). Therefore, sustained improvements in glycemic control and progressive reductions in body weight with exenatide treatment were associated with shifts toward a more favourable cardiovascular risk profile, particularly in patients that experienced the greatest weight loss. Whether exenatide exhibits direct cardiovascular effects similar to GLP-1 is currently unknown.
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###### 

Mean (±SE) change from baseline to 82 weeks in lipids and sitting blood pressure (n=265) ([@b41])

  Parameter                         Baseline (±SE)   Δ From baseline (±SE)   95% confidence interval
  --------------------------------- ---------------- ----------------------- -------------------------
  TC (mmol/L)                       4.82 ± 0.06      −0.07 ± 0.05            −0.17, +0.04
  HDL-C (mmol/L)                    0.98 ± 0.01      +0.12 ± 0.01            +0.09, +0.14
  LDL-C (mmol/L)                    2.98 ± 0.06      −0.04 ± 0.05            −0.13, +0.06
  Apo B (g/L)                       0.92 ± 0.02      −0.01 ± 0.01            −0.04, +0.01
  Triglycerides (mmol/L)            2.70 ± 0.13      −0.42 ± 0.11            −0.63, −0.20
  Systolic blood pressure (mmHg)    128.59 ± 0.84    −1.48 ± 1.01            −3.46, +0.51
  Diastolic blood pressure (mmHg)   78.66 ± 0.48     −3.24 ± 0.58            −4.37, −2.10

**Abbreviations:** Apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

Safety
------

Across the pivotal clinical trials, exenatide was generally well tolerated. Adverse events were mostly gastrointestinal in nature (nausea and vomiting) ([@b11]; [@b23]; [@b41]; [@b12]). Nausea, the most common treatment-emergent adverse event (exenatide 44%, placebo 18%), was mostly mild to moderate in intensity and diminished over time. Withdrawal due to nausea was approximately 4%.

Consistent with its glucose-dependent mechanism of action, most episodes of hypoglycemia were mild to moderate in intensity with one severe event that did not require medical assistance. Hypoglycemia was rarely observed in patients treated with the combination of exenatide and metformin and was similar in incidence to patients treated with placebo and metformin (exenatide 10 μg, 5%; placebo, 5%) ([@b23]). In contrast, the incidence of hypoglycemia was increased over that of placebo when exenatide was used in combination with a sulfonylurea (exenatide 10 μg, 32%; placebo, 8%) ([@b11]; [@b41]). Initial reduction of sulfonylurea dosage may limit the risk of hypoglycemia associated with such therapies upon initiation of exenatide treatment ([@b41]).

Approximately 40% of exenatide-treated patients developed anti-exenatide antibodies irrespective of background therapy ([@b11]; [@b23]; [@b41]). The majority of these antibodies were of low-titer with no apparent clinical consequence. A small proportion of exenatide-treated patients (6%) developed high-titer antibodies (≥1/625), of which 3% showed attenuated glycemic effects and 3% did not ([@b12]). These findings, along with those from recent trials, indicate that the presence of antibodies is not predictive of the magnitude of clinical response, incidence, or type of adverse events.

Summary
=======

Exenatide is a first in class incretin mimetic agent currently approved in the US as an adjunct to metformin and/or sulfonylureas for the treatment of type 2 diabetes. Exenatide improves glycemic control in patients with type 2 diabetes by significantly reducing HbA~1c~, and both fasting and postprandial hyperglycemia, through multiple mechanisms of action. The actions of exenatide include acute beta-cell effects (enhancement of glucose-dependent insulin secretion; restoration of first-phase insulin secretion), regulation of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake. Mounting evidence implicates post-meal hyperglycemia as a stronger predictor of the development of vascular complications than FPG. Since aberrant first-phase insulin secretion and impaired suppression of endogenous glucose production are major contributors to postprandial hyperglycemia, the effects of exenatide to target these defects, and normalize glucose excursions in patients with type 2 diabetes are likely to be clinically significant.

Obesity, the development of type 2 diabetes, and vascular risk are strongly linked. There is increasing evidence that weight loss can be beneficial in both the prevention and treatment of type 2 diabetes, but it is also recognized that this is difficult to achieve in a majority of patients. Improvements in glycemic control with exenatide were coupled with progressive weight reductions, which represents a distinct therapeutic benefit for patients with type 2 diabetes not adequately controlled with metformin and/or sulfonylurea therapy. In particular, potential reductions in body weight in patients with type 2 diabetes may have a positive impact on the development of vascular complications and long-term patient outcomes.
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